{
  "doc_id": "2018-10-01_Informationen-zVT_Lenvatinib-D-379",
  "created_date": "2017",
  "country": "AT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Criteria Vergleic",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "and",
      "text": "As As at: zur zur Bestachthherapi",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "and and Sy",
      "text": "221 Lenvatinib_",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "comparator comparator therapy: 5 5 § 6 VerfO G-BA",
      "text": "Lenvatinib [hepatocellular hepatocellular carcinoma]",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "5 5 § 6 VerfO",
      "text": "treatment treatment (corresponding to CCV) transarterial transarterial (chemo) embolisation (TACE or TAE) are not (more) eligible.",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Brand name",
      "text": "carcinoma carcinoma (generically) carcinomas carcinomas (5. 5.1). Nexavar® patients. patients.",
      "start_page": 3,
      "end_page": 5
    },
    {
      "heading": "Systematic research:",
      "text": "web web sites: MEDLINE MEDLINE (PubMed), quality. quality.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Indication:",
      "text": "al. al., with with ediate- of of ar",
      "start_page": 5,
      "end_page": 8
    },
    {
      "heading": "Cochrane reviews",
      "text": "• meetings • the the CPMP/ CVMP/ 049/ 01-al. al., chemoembolisation chemoembolisation (the the cancer), sorafenib sorafenib (cancer cancer growth), chemotherapy chemotherapy and",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "3. Outcome presentation",
      "text": "• life life (and and health), stay. stay. • pregnancy. pregnancy.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Systematic reviews",
      "text": "vein vein (MPV) o o (PVB). tumour tumour osis: eta-analysis eta-analysis osmalen",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "al., 2017",
      "text": "cellular cellular population: Intervention Intervention / comparator: s s Endpoints: overall survival (_OS), search search period: of of studies/patients included (total): of of studies: Newcastle–Ottawa Scale",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "3. Outcome presentation",
      "text": "• Median __MEDTERM0_ (95% CI) was eight (5-15) were were 29% (20%-40%), 4% (1%-11%), and 1% (0%), respectively. • Only 1% and and 18% complications. complications. • patients patients (p < 0.001), rates rates (14% vs. 16%).",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "patients patients (case case reports), of who",
      "text": "151 (17.7%) of of studies: Programme Programme (CASP) items items (for for practice?) size. size.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Quality of studies: to to provide",
      "text": "scored scored ‘evidence. evidence.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "• patients patients (45.0%).",
      "text": "of of these",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "patients (84%) surgery. surgery.",
      "text": "• patients patients (5.3%); reported. reported. • in in 10% in in 75%.",
      "start_page": 11,
      "end_page": 12
    },
    {
      "heading": "3. Outcome presentation",
      "text": "Quality of studies: quality. quality.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "• one-year one-year (risk ratio: 0. 0.85– 1.03, p=0.16), two-year",
      "text": "observed. observed. • treatments. treatments. • toxicity toxicity after",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "found found (risk ratio: 1. 1.08–1.92, p=0.01),",
      "text": "of of Authors: dysfunction dysfunction (affects affects __MEDTERM0_) comorbidities comorbidities (affect affect survival) metabolites. metabolites.",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "2016 [23]; Kong",
      "text": "2014 2014 [8]; al. al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2013 [15]; Liu Z",
      "text": "[12]; al. al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2014(3); Huo YR",
      "text": "Use Use (CPMP) Products Products (CHMP) 2005. 2005.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "et al., 2015 [7].",
      "text": "Use Use (CHMP) 2002. 2002.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "3. Outcome presentation",
      "text": "• groups groups (hazard ratio [HR]: 0.82; 95% CI: 0.69 – 0.97; p=0.02). •[...] trials trials (MCTs) review. review.",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "December 2013.",
      "text": "of of studies/patients included: studies studies (control control trials) the the studies: trials. trials.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "3. Outcome presentation",
      "text": "medicine. medicine.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "3. Outcome presentation",
      "text": "• the the studies: placebo1 placebo1 EMEA/ MB/ 049/ 01-Use Use (CPMP) Regulation Regulation (EEC) No 2377/ use use (p. p. • Products Products (CPMP) Use Use (Council Regulation (EEC) No 2377/ 90). EMEA/ Use Use (EMEA) Products Products (CPMP) rate rate (n=5 studies): • higher higher • the the studies: complications. complications.",
      "start_page": 17,
      "end_page": 23
    },
    {
      "heading": "search search (request update): up to 07/ 2012",
      "text": "Number of studies/patients included (total): 5 (n=1462) of of studies: reviews reviews (T. T.) of of trials: DCR DCR (n = 3 studies): • an an 85% the the placebo",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "group (1. 1.85; 95% 2. 2.20; P<0.001;",
      "text": "I2=0.0%) TTP (n=5 studies): • placebo placebo (HR, 0.61; 95% 0. 0.73; P<0.001; I2 = 31.8%) Overall Survival (N=4 studies):",
      "start_page": 23,
      "end_page": 24
    },
    {
      "heading": "Guidelines",
      "text": "• hepatocellular hepatocellular carcinoma? forward. forward. • ageste ageste empfehlthodikulation/ Diag Diag kung: the the Guideline: rule-line. rule-line.",
      "start_page": 24,
      "end_page": 26
    },
    {
      "heading": "Evidence Evidence Graduation",
      "text": "7. 7.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "recommendation recommendation graduation",
      "text": "mandaters mandaters (1. 1.7). statements statements (2. 2.3) level level (2. 2.1) recommendation recommendation (level of recommendation). guideline guideline (see Table 8), recommendations. recommendations.",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "of of specific",
      "text": "opinions. opinions.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Practice Practice (GCP) of of ‘practice. practice.",
      "text": "used used (to be/ may be) recommendations. recommendations. • staging. staging. [Methods] be be considered: [McP; strong consensus] advanced advanced Pfortaderthrombosis: [GCP; severe consensus].",
      "start_page": 29,
      "end_page": 34
    },
    {
      "heading": "See Annex!",
      "text": "agreement. agreement.",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "search search strategy",
      "text": "Cochrane Library (Assessment Assessment database) 10. 10.2017",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# search question",
      "text": "1 MeSH description: [Carcinoma, Hepatocellular] treatments treatments #2 MeSH dictionary: [Liver Neoplasms] tree tree #3 hepatoma*::or or HCC:ti;or or hepatocarcinoma*:cell cell carcinoma***:ti/ hepatocellular:ti or ‘hepatobiliary: ti #5 cancer*:ti or tumour* or tumour*: ti or neoplasm*:tior carcinomas* or adenocarcinomas*:Ti or malignant*:ti #6 #4 and #5 #7#1 or #3 #8 #8",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# search question",
      "text": "#Carcinoma, Hepatocellular[MeSH Terms] #2 Liver Neoplasms[Mh:noexact] #3 ((hepatocarcinoma*[Tittle] OR HCC[Title]",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "# search question",
      "text": "[MeSH Terms] #2 Liver Neoplasms[mh:noexp] #3 ((hepatocarcinoma*[title]) OR HCC[Title]",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "Literature:",
      "text": "0 0 [online].",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "heading heading < 5 5 § 6 VerfO>",
      "text": "2000 2000 - 2001 2001 - 29.07.2000",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <Tradename>",
      "text": "{Invented name}} [Injected Name} [completed completed nationally] [Leaflet. Leaflet.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Tradename> (column 1)",
      "text": "Row 1: Row 2: \" Row 3: Row Row 4: ' Indication Row 5: ATC code \" Row 6: ↔ (advice advice request/ Row Row 7: Row Row 8: ' Row 9: ⋅ Row 10: ύ Row 11: be be evaluated:' Row 12: Ά Row 13: __MEDTERM0_ ‘ Provisionally planned indication: Row 14: Row Row 15: Lenvima® Row 16: Mitomycin L01DC03 (generic) Row 17:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Tradename> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: ormation Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Tradename> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: ) Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Tradename> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <Indication:> (from previous page)",
      "text": "• 26 days • 27 days • 25 days • 24 days • 30 days • 31 days • 23 days • 28 days • 29 days • 21 days • 20 days • 14 days • 13 days • 12 days • 16 days • 15 days • 11 days • 10 days • 19 days • 17 days • 22 days •",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading <Indication:> (from previous page)",
      "text": "Row 1: G-BA, 2015[5] carcinoma carcinoma (HCC): See See also: G- BA, 2015",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading < Cochrane reviews>",
      "text": "• Products Products (CPMP) assessed assessed transarterial",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading < Systematic reviews>",
      "text": "studies. studies.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heading heading < Systematic reviews>",
      "text": "Row 1: al. al., 2017 [19]. vein vein (MPV) sectors sectors (PVB). Row 2: 2. Methodology",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heading heading <score score >",
      "text": "• Meeting% population population • meeting% PVT. PVT. • Intervention/ comparator: PVT PVT Endpoints: overall survival (__MEDTERM0_), research research period: enrolled enrolled studies/patients (total): of of studies: Newcastle–Row Row 2: the the studies: disease disease (the the text).",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "patients patients (84%) surgery. surgery.>",
      "text": "study study (total): patients patients (case case reports), 151. 151. • in in 10% in in 75%. Row 3: 4.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading < found found (risk ratio: 1. 1.08–1.92, p=0.01),>",
      "text": "dysfunction dysfunction (affects affects OS) comorbidities comorbidities (affect affect survival) tumour tumour treatment",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading < 20143; Huo YR>",
      "text": "increased. increased.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <et al., 2015 127.>",
      "text": "following following table: http: / /eudra. eudra. org/@int. int.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <et al., 2015 127.> (column 2)",
      "text": "• Products Products (CPMP) Regulation Regulation (EEC) No 2377/ use use (p. p.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading <score score >",
      "text": "HCC. HCC.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heading heading <score score >",
      "text": "TACE TACE + sorafenib. Row 2: 2. Methodology Population: HCC HCC Intervention/ comparator: TACE vs. • TACE TACE + progression progression (TTP) Tace Tace + TACE TACE alone; hazard ratios (HRs) 61 61 (95% CI 0.39– p p = 0.031). • survival survival (__ MEDTERM6__) treated treated with",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heading heading <score score > (column 2)",
      "text": "which which included: studies studies (randomized randomized controls) 2013. 2013. • TACE TACE + progression progression (TTP) Tace Tace + TACE TACE alone; hazard ratios (HRs) 61 61 (95% CI 0.39– p p = 0.031). • survival survival (__ MEDTERM5__) tace tace + thance thance + alone. alone. • Row Row 4:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heading heading <score score >",
      "text": "were were adopted:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <3. Outcome> (from previous page)",
      "text": "trials trials (4. 4.3).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "heading heading <3. Outcome> (from previous page)",
      "text": "• Quality Quality (AHRQ) pre-specified. pre-specified.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "heading heading <3. Outcome> (from previous page)",
      "text": "survival survival (n=7 studies): • __medterm8__ __medterm8__ • (HR=0.74, 95% CI: 0. 0.90; P=0.002) • significant significant (P=0.000, I2=77.0%) • subgroup analysis: of of 1–2 (HR = 0.77, 95% CI : 0, 0, P=0.05), invasion invasion (MVI) and/spread spread (EHS)",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "heading heading <score score > (column column 2)",
      "text": "with with REI/ with with PEI/survival survival (n=7 studies): • __medterm7__ __medterm7__ • (HR=0.74, 95% CI: 0. 0.90; P=0.002) • significant significant (P=0.000, I2=77.0%) • subgroup analysis:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "heading heading <3. Outcome> (from previous page)",
      "text": "increased. increased. • __MEDTERM; status status • Rate Rate (N=5 Studies): Methodology Population: HCC HCC Intervention: drug drug (antitumor antitumor drug) Comparator: arterial embolism Endpoints: primary: survival survival (OS); secondary: reduction reduction Study/ included included (total): 5 (n=582) of of studies: Evaluation. Evaluation.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <score score > (column column 4)",
      "text": "of of studies: bias bias summary:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <3. Outcome> (from previous page)",
      "text": "• events events (n=k.A.) • events events were:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <score score > (column column 2)",
      "text": "• events events (n=k.A.) • AE. AE.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading < group (1. 1.85; 95% 2. 2.20; P<0.001;>",
      "text": "clinical clinical trials/patients (total) survey. survey.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "headed headed < group (1. 1.85; 95% 2. 2.20; P<0.001;> (column 4)",
      "text": "of of studies/patients included (total): 5 (n=1462) the the studies: reviews reviews (T. T.)",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading < Guidelines >",
      "text": "following following languages: http: / /eudra. eudra. org",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading < Guidelines >",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: Row Row 7: Row Row 8: Row Row 9: Row Row 10: Row Row 11: firm firm principles",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading < Guidelines > (column 4)",
      "text": "• onwards. onwards.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading (from previous page)",
      "text": "Row 1: Row 2: DKG, 2013 [9.10]. Diagnostics and Question/Aim: Row Row 3: Methodology",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "heading heading < after after Oxford>",
      "text": "Eow 1: of of guideline: rule rule (http://www.awmf.org/Guidelines/aw mf-regelwerk.html). workshop workshop (Kick-off meeting). developed. developed.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading < to to Oxford> (from previous page)",
      "text": "Row 1:",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading < Make recommendations >",
      "text": "electors electors (1. 1.7). statements statements (2. 2.3) level level (2. 2.1) recommendation recommendation (level of recommendation) for recommendations.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Table under heading< Practice Practice (GCP) considered considered >",
      "text": "2 EMEA/ MB/ 049/ 01-2001 2001 • 2000 2000 • 26.07.2000",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading< Practice Practice (GCP) considered considered >",
      "text": "Row 1: Row Row 2: Row Row 3: Brecommendationshould Row 4: Crecommended open",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading< Practice Practice (GCP) considered considered >",
      "text": "Row 1: Row Row 2: Strong consensus > 95% Row Row 3: Consensity > 75 – 95% Row Row 4: Majority support> 50 – 75% Row Row 5: Dissens < 50% of vote holders",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Table under heading< Practice Practice (GCP) considered considered >",
      "text": "Row 1: Row Row 2: Stove Stove < portal portal hypertension",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "Row 1: Stomach Stomach < Stod Stod < Invasion Invasion Child- Child Child -Treatment Treatment recommendations:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "Row 1: Row Row 2: Stomach Stomach < Rouw Rouw 3: A3ECoG 0↔1 Stod < Row Row 4: A4ECooG 0⋅1 Stoll < Row Row 5: BECOCG 0'Row Row 6: Row Row 7: DECOG 3-4egalChild -Pugh C",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "Row 1: Evidence-based Evidence-based recommendation: • Trans-Arterial chemoembolisation (TACE) following following criteria: ECOG ECOG ≤ B. B. [LoE: 1b; GoR: A; strong consensus] Consensus- based recommendation:",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "[GCP; strong consensus] Evidence-based statement: • progress. progress.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "[LoE: 2a; GoR: BG: 3b; strong consensus] Guidelines-based recommendation: • progress. progress.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "heading heading < As ‘Practice Practice (GCP)",
      "text": "Row 1: LoE/ GoR Row 2: Recommendations",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < See Annex!>",
      "text": "Row 1: See Annex!",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "heading heading < See Annex!>",
      "text": "Regulation Regulation (EEC) No 2377/ use use (p. p.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "heading heading <# Suchfrage>",
      "text": "Row 1: #Suchfrage Row 2: #1MeSH description: [Carcinoma, Hepatocellular] Row Row 3: #2 MeSH descriptive: [Liver Neoplasms] Row Row 4: #3hepatoma*::or or HCC:ti;or or hepatocarcinoma*:ti.ab;next next carcinom*: cell cell carcinoma*:Row Row 5: #4 liver:ti or \"hepatocellular\": ti. or \"hapatobiliary\":ti Row 6: #5cancer*:ti or tumour* or tumor* in :ti. neoplasm*: ti or carcinomas* or adenocracinoma*:iti or malignan*:di Row 7: #6",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <# Suchfrage>",
      "text": "< [] < {] < < < {> < {} < {< {] > < {...} > {> } {> {} {} }} { { {}} {} 0} {] {} 002} {[} {_} {*} {Y} {Name} {#} {((}} < [}}",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "heading heading <# Suchfrage>",
      "text": "Row 1: (systematic*[Title/Abstract] AND overview*[Title/AbStract]) OR meta-analy*[Abstract} OR (meta[Tidle/ Abstract,] AND analyz*[Tettle/abstract.])",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <# Suchfrage>",
      "text": "[Invented name] [INVENTED Name] [completed completed nationally]",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <# search question> (column 1)",
      "text": "Row 1: Row 2: #14 Row 3: #15",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <# search question> (column 1)",
      "text": "Row 1: # Suchfrage Row 2: #1 Row 3: #2 Row 4: #3 Row 5: #4 Row 6: #5 Row 7: #6 Row 8: #7 Row 9: #8 Row 10: #9",
      "start_page": 38,
      "end_page": 38
    }
  ]
}